TY - JOUR. T1 - Not all insulin-like growth factor-binding proteins (IGFBPs) are detectable by western ligand blotting. T2 - Case studies of pc 12 pheochromocytoma and rat anterior pituitary igfbps and proteolyzed igfbp-3. AU - Ocrant, Ian. AU - Fay, Charles T.. AU - Pham, Hung. AU - Rosenfeld, Ron G.. PY - 1992/7. Y1 - 1992/7. N2 - We studied the limitations of the Western ligand blot (WLB) for detecting insulin-like growth factor-binding proteins (IGFBPs). PC12 rat pheochromocytoma cells and rat anterior pituitary cells (AP) secrete IGFBPs that cannot be detected by WLB. We used affinity labeling, WLB, dot blotting, competitive binding, ion exchange chromatography, and deglycosylation to characterize these IGFBPs. These IGFBPs were compared with pregnancy protease-derived IGFBP-3 fragments that also bind insulin-like growth factors (IGFs), but are not detectable by WLB. We showed that PC12 IGFBP is cationic, not glycosylated, with 25, 500 mol wt reduced (18, 500 unreduced), with high affinity ...
Title of Dissertation: FUNCTION OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 7(IGFBP7) IN HEPATOCELLULAR CARCINOMA By Dong Chen. Purpose: Hepatocellular carcinoma (HCC) is a highly virulent malignancy with no effective treatment, thus requiring the development of innovative and effective targeted therapies. The oncogene Astrocyte Elevated Gene-1 (AEG-1) plays a seminal role in hepatocarcinogenesis and profoundly downregulates Insulin-like Growth Factor Binding Protein-7 (IGFBP7). The present study focuses on analyzing potential tumor suppressor functions of IGFBP7 in HCC and the relevance of IGFBP7 downregulation in mediating AEG-1 function. Experimental Design: IGFBP7 expression was detected by immunohistochemistry in HCC tissue microarrays by real-time PCR and ELISA in human HCC cell lines. Dual Fluorescence in situ hybridization was performed to detect loss of heterozygosity at the IGFBP7 locus. Stable IGFBP7- overexpressing clones were established in the background of AEG-1- overexpressing human
Insulin-like growth factor-binding protein 6 contains a PF00086 domain.. Insulin-like growth factor-binding protein 6 contains a PF00219 domain.. Insulin-like growth factor-binding protein 6 is proteolytically cut by matrix metallopeptidase-2 (M10.003) cleavage. CLRR-EGQP.. ...
TY - JOUR. T1 - Structural and immunological comparison of insulin-like growth factor binding proteins of cerebrospinal and amniotic fluids. AU - Rosenfeld, R. G.. AU - Pham, H.. AU - Conover, Cheryl A. AU - Hintz, R. L.. AU - Baxter, R. C.. PY - 1989. Y1 - 1989. N2 - The insulin-like growth factors (IGFs) found in plasma and a variety of other body fluids are complexed to specific binding proteins (BPs). The cDNA for a 25K IGF-BP was recently cloned and sequenced, and the primary structure of the BP deduced. This BP is found in amniotic fluid, decidual tissues, conditioned medium from HepG2 human hepatoma cells, and fetal plasma. An additional small IGF-BP has been identified in human cerebrospinal fluid (CSF). We now demonstrate that the IGF-BP found in CSF is structurally and immunologically distinct from that found in HepG2 conditioned medium. While the latter BP has approximately equal affinities for IGF-I, and -II, the CSF BP has a 10- to 20-fold greater affinity for IGF-II. In affinity ...
Expression of insulin-like growth factor binding protein 5 (IGFBP5) is strongly induced upon activation of hepatic stellate cells and their transdifferentiation into myofibroblasts in vitro. This was confirmed in vivo in an animal model of liver fibrosis. Since IGFBP5 has been shown to promote fibrosis in other tissues, the aim of this study was to investigate its role in the progression of liver fibrosis. The effect of IGFBP5 was studied in LX2 cells, a model for partially activated hepatic stellate cells, and in human primary liver myofibroblasts. IGFBP5 signalling was modulated by the addition of recombinant protein, by lentiviral overexpression, and by siRNA mediated silencing. Furthermore, the addition of IGF1 and silencing of the IGF1R was used to investigate the role of the IGF-axis in IGFBP5 mediated effects. IGFBP5 enhanced the survival of LX2 cells and myofibroblasts via a |50% suppression of apoptosis. This effect of IGFBP5 was not modulated by the addition of IGF1, nor by silencing of the
Vascular function is greatly influenced by growth factors and regulatory molecules that can interact with each other in a complex pattern in the vascular wall. In this thesis we studied how different substances of special interest in the pathogenesis of vascular disease interact and regulate each others expressions in endothelial cells and vascular smooth muscle cells (VSMCs).. In VSMCs, angiotensin II was shown to delay PDGF-BB induced cell growth. This transient inhibitory effect of angiotensin II was mediated by the AT1-receptor, did not involve autocrine action of transforming growth factor-ß1 (TGF-ß1) and acted at a site downstream of PDGF-ß receptor phosphorylation.. The interaction of the insulin-like growth factor-system (IGF-system) with various growth factors, glucose and nitric oxide (NO) was studied in vascular cells. Vascular endothelial growth factor (VEGF) and transforming growth factor-ß1 (TGF-ß1) regulated the expression of insulin-like growth factor-binding proteins ...
Introduction: Heart failure with preserved ejection fraction (HFpEF) is associated with considerable morbidity and mortality. Insulin-like growth factor-binding protein 7 (IGFBP7) is a cell cycle arrest biomarker associated with abnormal diastology and prognosis in HF with reduced EF (HFrEF). Its role in patients with HFpEF is unknown.. Hypothesis: IGFBP7 will be associated with adverse outcomes in HFpEF.. Methods: Baseline (BL) IGFBP7 (n=302; placebo=154, irbesartan=148) and 6 month change (Δ; n=293; placebo=147, irbesartan=146) were measured and correlated with clinical data, biomarkers, estimated glomerular filtration rate (eGFR), and the primary outcome of all-cause mortality (ACM) or cardiovascular hospitalization (CVH) in patients from the Irbesartan in HFpEF (I-PRESERVE) Trial; secondary outcomes included HF events.. Results: Median BL IGFBP7 concentration was 218 ng/mL, higher than previously seen in patients with HFrEF. BL IGFBP7 was correlated with age (R2=0.13; P,0.0001) and other ...
Reactivity: Chicken, Human, Monkey and more. Compare 11 different IGFALS ELISA Kits & buy the right one directly at antibodies-online.com!
Reaktivität: Huhn, Human, Affe and more. 16 verschiedene IGFALS ELISA Kits vergleichen. Alle direkt auf antikoerper-online.de bestellbar!
Introduction: In this study, we compared human placental gene expression patterns of IGF from pregnancies that ended with preterm delivery versus full term pregnancies as controls. We also assessed differences in clinical characteristics in the two groups. Materials and Methods: We used real-time PCR to assess gene expression patterns of IGF in human placental samples from 104 preterm and 140 full term pregnancies (control group) at the time of delivery. Clinical data were collected from our computerized database. Results: Pre-gestational Body Mass Index (BMI) was not significantly different in the two groups. In the preterm delivery group, the proportion of smokers was 26.9%, significantly higher than in the control group (7.1%, p,0.05). Preterm delivery began with premature rupture of membranes in 70.2% and spontaneous uterine activity in 29.8%. History of preterm delivery was present in 14.4% in the preterm delivery group compared to only 4.3% of the control group (p,0.05). In preterm ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
The present study establishes the cellular sites of expression of several components of the IGF system in adult rat liver, a predominant source of circulating IGF-I in adult rat and other mammals (17, 19). As expected, IGF-I mRNA was highly expressed in hepatocytes. IGF-I mRNAs were also demonstrated in Kupffer cells and hepatic endothelial cells. These findings indicate that IGF-I secreted from nonparenchymal cells may contribute to the circulating pool of IGF-I derived from liver, albeit at lower levels than IGF-I derived from hepatocytes. Kupffer and endothelial cells play a key role in immune recognition, cytokine production, and immune cell recruitment within the liver (11). In other systems, IGF-I expression by macrophages and endothelial cells may participate in processes such as wound healing (28) and vascular repair after endothelial damage (43) and in the pathogenesis of pulmonary and intestinal fibrosis (29, 51). Our present findings raise the possibility that IGF-I derived from ...
The views presented here are those of the author and are not to be construed as official or reflecting the views of the Uniformed Services University of the Health Sciences, the Department of Defense or the U.S. Government ...
Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an IGFBP7 agent if t
Reaktivität: Huhn, Rind (Kuh), Hund and more. 110 verschiedene IGFBPI ELISA Kits vergleichen. Alle direkt auf antikoerper-online.de bestellbar!
IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors.
IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors ...
CS23-02 Insulin-like growth factors (IGFs) affect proliferation, differentiation, apoptosis, and angiogenesis. Several studies indicate that high serum levels of IGF1 are risk factors for common human cancers. The effects of IGFs are modulated by insulin-like growth factor binding proteins (IGFBPs). It has been demonstrated that the administration of molecules that interrupt IGF action leads to impressive antineoplastic activity in in vitro and in vivo models of a variety of cancers. Recent studies have implicated the IGF-mediated signaling pathway in the resistance to anti-epidermal growth factor receptor (EGFR) therapies, suggesting that a combinational regimen targeting both EGFR and IGFR simultaneously may yield greater anticancer activity than strategies that target a single receptor. We designed the current study to investigate the effects of blocking the IGF-1R signaling pathway, either single or in combination with anti-EGFR strategies, on non-small cell lung cancer (NSCLC) and head and ...
This gene is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. The protein binds both insulin-like growth factors (IGFs) I and II and circulates in the plasma. Binding of this protein prolongs the half-life of the IGFs and alters their interaction with cell surface receptors. [provided by RefSeq, Jul 2008 ...
IGFBP3 - IGFBP3 (untagged)-Human insulin-like growth factor binding protein 3 (IGFBP3), transcript variant 1 available for purchase from OriGene - Your Gene Company.
IGFBP1 - IGFBP1 (untagged)-Human insulin-like growth factor binding protein 1 (IGFBP1) available for purchase from OriGene - Your Gene Company.
1-7 days: ≤0.7 mcg/mL. 8-14 days: 0.5-1.4 mcg/mL. 15 days-11 months: unavailable. 1 year: 0.7-3.6 mcg/mL. 2 years: 0.8-3.9 mcg/mL. 3 years: 0.9-4.3 mcg/mL. 4 years: 1.0-4.7 mcg/mL. 5 years: 1.1-5.2 mcg/mL. 6 years: 1.3-5.6 mcg/mL. 7 years: 1.4-6.1 mcg/mL. 8 years: 1.6-6.5 mcg/mL. 9 years: 1.8-7.1 mcg/mL. 10 years: 2.1-7.7 mcg/mL. 11 years: 2.4-8.4 mcg/mL. 12 years: 2.7-8.9 mcg/mL. 13 years: 3.1-9.5 mcg/mL. 14 years: 3.3-10 mcg/mL. 15 years: 3.5-10 mcg/mL. 16 years: 3.4-9.5 mcg/mL. 17 years: 3.2-8.7 mcg/mL. 18 years: 3.1-7.9 mcg/mL. 19 years: 2.9-7.3 mcg/mL. 20 years: 2.9-7.2 mcg/mL. 21-25 years: 3.4-7.8 mcg/mL. 26-30 years: 3.5-7.6 mcg/mL. 31-35 years: 3.5-7.0 mcg/mL. 36-40 years: 3.4-6.7 mcg/mL. 41-45 years: 3.3-6.6 mcg/mL. 46-50 years: 3.3-6.7 mcg/mL. 51-55 years: 3.4-6.8 mcg/mL. 56-60 years: 3.4-6.9 mcg/mL. 61-65 years: 3.2-6.6 mcg/mL. 66-70 years: 3.0-6.2 mcg/mL. 71-75 years: 2.8-5.7 mcg/mL. 76-80 years: 2.5-5.1 mcg/mL. 81-85 years: 2.2-4.5 mcg/mL. Tanner Stages:. Males. Stage I: 1.4-5.2 ...
IGFB3 : Container/Tube: Preferred: Red top Acceptable: Serum gel Specimen Volume: 0.8 mL Collection Instructions: Spin down promptly. Additional Information: Indicate patients age and sex.
The longer a person lives with diabetes, the higher their risk of digestive issues. For a long time, it was unclear why, but an international study has found a possible culprit. Study researchers believe they have found that the liver of a person with Type 1 may produce an excessive amount of a protein that can hamper digestion, according to a Science Daily report.. By comparing the intestinal tissue of people with and without diabetes, researchers realized that the cells lining the intestinal tract of people with diabetes were damaged by a substance called insulin-like growth factor binding protein 3 (IGFBP3). Excess IGFBP3 can cause gastrointestinal issues like irritable bowel syndrome, delayed bowel movements, bloating, and lack of bowel control; collectively, these problems are known as diabetic enteropathy. IGFBP3 cells attach themselves to colonic stem cells, which are coincidentally responsible for repairing wounds in the intestinal lining. As these stem cells are damaged, they lose the ...
PAPPA Full-Length MS Protein Standard (NP_002572), Labeled with [U- 13C6, 15N4]-L-Arginine and [U- 13C6, 15N2]-L-Lysine, was produced in human 293 cells (HEK293) with fully chemically defined cell culture medium to obtain incorporation efficiency at Creative-Proteomics. This gene encodes a secreted metalloproteinase which cleaves insulin-like growth factor binding proteins (IGFBPs). It is thought to be involved in local proliferative processes such as wound healing and bone remodeling. Low plasma level of this protein has been suggested as a biochemical marker for pregnancies with aneuploid fetuses.
IGFBP7 antibody [3N37] (insulin-like growth factor binding protein 7) for WB. Anti-IGFBP7 mAb (GTX52799) is tested in Human samples. 100% Ab-Assurance.
IGFBP3 antibody [N2C3] (insulin-like growth factor binding protein 3) for IHC-Fr, WB. Anti-IGFBP3 pAb (GTX100454) is tested in Human, Mouse, Rat samples. 100% Ab-Assurance.
The protein encoded by this gene is a member of the DOK family of membrane proteins, which are adapter proteins involved in signal transduction. The encoded protein interacts with phosphorylated receptor tyrosine kinases to mediate neurite outgrowth and activation of the MAP kinase pathway. Unlike other DOK family proteins, this protein does not interact with RASGAP. This protein is up-regulated in patients with systemic sclerosis and is associated with fibrosis induced by insulin-like growth factor binding protein 5. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, Jun 2014 ...
Connect and collaborate with Casey Doucette at University of Maine Graduate School of Biomedical Sciences, with research interests in Insulin-like growth factor binding proteins and Hematopoietic stem cell niche, on Mendeley.
Zhong Y, Lu L, Zhou J, Li Y, Liu Y, Clemmons DR, Duan C. IGF binding protein 3 exerts its ligand-independent action by antagonizing BMP in zebrafish embryos. J
Pathol 185, In press (2015).. Asharani PV, Keupp K, Semler O, Wang W, Li Y, Thiele H, Yigit G, Pohl E, Becker J, Frommolt P, Sonntag C, Altmüller J, Zimmermann K Greenspan DS, Akarsu NA, Netzer C, Schönau E, Wirth R, Hammerschmidt M, Nürnberg P, Wollnik B, Carney TJ. Attenuated BMP1 function compromises Osteogenesis, leading to bone fragility in humans and zebrafish. Am J Hum Genet 90, 661-674 (2012).. Huang G, Greenspan DS. Roles of ECM in the function of metabolic tissues. Trends Endocrinol. Metab 23, 16-22 (2012).. Muir A, Greenspan, DS. Metalloproteinases in Drosophila to humans that are central players in developmental processes. J. Biol. Chem. 286, 41905-41911 (2011).. Kim B, Huang G., Ho W-B, Greenspan DS. Bone morphogenetic protein-1 processes insulin-like growth factor-binding protein 3. J. Biol. Chem. 286, 29014-29025 (2011).. Huang G, Ge G, Wang D, Gopalakrishnan B, Butz DH, Colman RJ, Nagy A, Greenspan DS. a3(V) collagen is critical for glucose homeostasis due to effects in islets ...
IGFBP5 is the most conserved member of the IGFBP family (11, 12) and has been reported to inhibit or potentiate IGF or acts as a growth factor itself in mammalian cells (9-12). Despite these findings, IGFBP5-deficient mice do not have overt phenotypes (19). Here, we showed that genetic deletion of zebrafish Igfbp5a causes body Ca2+ deficiency and premature death under regular laboratory conditions. The igfbp5a−/− mutant larvae exhibited clear and specific defects in NaR cell adaptive proliferation under Ca2+-deficient conditions. These results reveal a critical role of Igfbp5a in regulating organismal survival and calcium balance by promoting NaR cell proliferation under low-calcium states.. The lack of phenotype in IGFBP5-null or other IGFBP-null mice has been postulated to be due to the genetic redundancy in the mouse model (12). The use of CRISPR-Cas9 and TALEN to delete and edit genes suggest that the phenotype gap is also present in zebrafish. Many cases have been reported in which ...
The IGF axis: circulating IGFs are protected from degradation by forming complex with IGFBPs. IGFs, apart from their local functioning in an autocrine or a para
TY - JOUR. T1 - Effects of aromatase complex selective inhibition on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 circulating levels in breast cancer. AU - Ferrari, Leonardo. AU - Bajetta, Emilio. AU - Seregni, Ettore. AU - Martinetti, Antonia. AU - Zilembo, Nicoletta. AU - Noberasco, Cristina. AU - Buzzoni, Roberto. AU - Botti, Carlo. AU - Massaron, Simonetta. AU - Bichisao, Ettore. AU - Celio, Luigi. AU - Bombardieri, Emilio. PY - 1997. Y1 - 1997. N2 - The aim of our study is to evaluate insulin-like growth factor (IGF) and IGF binding protein (IGFBP)-3 circulating levels in postmenopausal women treated with type I aromatase inhibitor formestane for breast cancer. Sixty- three patients at their first relapse entered the trial and were randomly given formestane at 250 mg or 500 mg i.m. fortnightly. Effects of the endocrine treatment on IGF-1 and IGFBP-3 were measured before and during therapy at scheduled times. IGF-1 and IGFBP-3 seems to slightly increase in ...
We have previously demonstrated that insulin-like growth factor binding protein-5 (IGFBP-5) is upregulated following treatment of the mouse mammary epithelial cell line HC11 with lactogenic hormones (dexamethasone, insulin, and prolactin-DIP). In addition, we have also shown that IGFBP-5 is upregulated in mammary epithelial cells in vivo during involution of the rodent mammary gland. We have, therefore, postulated that there may be a dual regulation of IGFBP-5 expression during the temporally separated processes of differentiation and apoptosis of mammary epithelial cells. To test this hypothesis further, we have used a phenotypically differentiated model, which comprises primary cultures of mouse mammary epithelial cells grown on a layer of EHS (Engelbreth-Holm-Swarm) extracellular matrix. We show that lactogenic hormone treatment hydrocortisone, insulin, and prolactin-HIP) of these cultures induces the upregulation of IGFBP-5 thus replicating the results obtained with the HC11 cell line. In ...
Insulin-like growth factor binding proteins (IGFBPs) are known to be important modulators of the insulin-like growth factor (IGF-I). However, their precise role is as yet unclear. Further, recent studies have indicated that IGFBP-3 has a receptor mediated growth inhibitory response of its own. In the present study, we quantified the binding characteristics of IGFBP-3 to bovine aortic endothelial (BAE) cells. Binding studies at 4 oC were conducted and a specific binding curve for IGFBP-3 was obtained. IGFBP-3 was found to bind with an equilibrium dissociation constant (KD) value of 3.1 x 10-10 M. The role of heparan sulfate proteoglycans (HSPG) in the IGFBP-3 binding mechanism was also examined. It was seen that inactivation of the cell surface HSPGs with 75 mM sodium chlorate did not affect IGFBP-3 binding. Further, there have been reports of inhibition of IGFBP-3 binding by heparin in the media. Hence, the most probable interaction of HSPG with IGFBP-3 occurs in the extracellular region, with ...
IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF- I and IGF-II. IGF-BP-6 plays a role in lipoprotein assembly and dietary cholesterol absorption. in addition to its acyltransferase activity, it may act as a ligase. may provide cholesteryl esters for lipoprotein secretion from hepatocytes and intestinal mucosa.Human recombinant IGF-BP-6 produced in E. coli is a single, non-glycosylated polypeptide chain containing the amino acids 148-240 and having a molecular mass of 20 kDa including a 4 kDa His tag. It is purified by using proprietary chromatographic techniques ...
anti-Insulin-Like Growth Factor Binding Protein, Acid Labile Subunit (IGFALS) (Middle Region) antibody ABIN634631 from antibodies-online
Pappalysin-1, also known as pregnancy-associated plasma protein A, is a protein encoded by the PAPPA gene in humans. PAPPA is a secreted protease whose main substrate is insulin-like growth factor binding proteins. Pappalysin-1 is also used in screening tests for Down syndrome. This gene encodes a secreted metalloproteinase which cleaves insulin-like growth factor binding proteins (IGFBPs). PAPPAs proteolytic function is activated upon collagen binding. It is thought to be involved in local proliferative processes such as wound healing and bone remodeling. Low plasma level of this protein has been suggested as a biochemical marker for pregnancies with aneuploid fetuses (fetuses with an abnormal number of chromosomes). For example, low PAPPA may be commonly seen in prenatal screening for Down syndrome. Low levels may alternatively predict issues with the placenta, resulting in adverse complications such as intrauterine growth restriction, preeclampsia, placental abruption, premature birth, or ...
European Cells & Materials Journal - Open and Free Access - The Official Research Journal of AOCMF, AOTrauma, European Orthopaedic Research Society (EORS), Swiss Society for Biomaterials (SSB) and Tissue & Cell Engineering Society (TCES)
Trfp (GFP-tagged) - Mouse Trf (TATA binding protein-related factor)-proximal protein homolog (Drosophila) (cDNA clone MGC:63299, 10 µg.
Shop Oxysterol-binding protein-related protein ELISA Kit, Recombinant Protein and Oxysterol-binding protein-related protein Antibody at MyBioSource. Custom ELISA Kit, Recombinant Protein and Antibody are available.
Adjuvant-induced arthritis in rats is associated with growth failure, hypermetabolism and accelerated protein breakdown. The aim of this work was to study the effects of adjuvant-induced arthritis on GH and insulin-like growth factor-I (IGF-I). Arthritis was induced by an intradermal injection of complete Freunds adjuvant and rats were killed 18 and 22 days later. IGF-I and GH levels were measured by radioimmunoassay. Pituitary GH mRNA was analyzed by northern blot and IGF binding proteins (IGFBPs) by western blot. Arthritic rats showed a decrease in both serum and hepatic concentrations of IGF-I. On the contrary, arthritis increased the circulating IGFBPs. The serum concentration of IGF-I in the arthritic rats was negatively correlated with the body weight loss observed in these animals. Arthritis decreased the serum concentration of GH and this decrease seems to be due to an inhibition of GH synthesis, since pituitary GH mRNA content was decreased in arthritic rats (p,0.01). These data ...
Aim:To correlate placental protein levels of insulin-like growth factor (IGF)-I and insulin-like growth factor binding protein (IGFBP)-1, with previously determined levels of IGF-I and IGF-II mRNA expression, and the micronutrients zinc and iron, and maternal and newborn anthropometry. Methods: Placental samples were collected from rural field sites in Pakistan. Samples were divided into small and large for gestational age groups (SGA and LGA, respectively). IGFBP-1 levels were assessed using Western immunoblotting. IGF-I protein levels were assessed using ELISA techniques. IGF mRNA expression, zinc, and iron, were quantified as previously described and were used for comparative Purposes only. Results: Thirty-three subjects were included (SGA, n = 12, LGA n = 21). Higher levels of IGFBP-1 were seen in the SGA group (p | 0.01). IGFBP-1 correlated positively with maternal and infant triceps skin-fold thickness in the LGA and SGA groups, respectively (p | 0.05). Significantly lower IGF-I protein levels
Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective ...
Litter size is among the most important traits in swine breeding. However, information on the genetics of litter size in pigs is lacking. In this study, we identified single nucleotide polymorphisms (SNPs) in the insulin-like growth factor binding protein 2 and 3 (IGFBP2 and IGFBP3) genes in Berkshire pigs and analyzed their association with litter size traits. The IGFBP2 SNP was located on chromosome 15 intron 2 (455, A , T) and the IGFBP3 SNP was on chromosome 18 intron 2 (53, A , G). The AT type of IGFBP2 and the GG type of IGFBP3 had the highest values for all litter size traits including total number born (TNB), number of pigs born alive, and breeding value according to TNB ...
3877 The geldanamycin derivative, 17-allyamino-17-demethoxygeldanamycin (17-AAG), is a selective HSP90 inhibitor that is now under clinical investigation. The biomarkers that have been used in 17-AAG clinical trials to date are HSP70, Raf-1 and CDK4. HSP70 was induced during 17-AAG treatment, whereas Raf-1 and CDK4 were repressed. All three biomarkers have to be analyzed by western blot of cellular samples, either from tumor biopsy or PBMC cells isolated from patient blood. This analytical method is time-consuming and laborious. We have identified two new biomarkers, IGFBP2 and HER-2 ECD (HER-2 extracellular domain), both of which can be readily detected in patient sera by ELISA. IGFBP-2 is an Insulin-like Growth Factor binding protein that modulates the activity and facilitates the transportation of IGF and is regulated via the PI3K/AKT pathway. Inhibition of HSP90 causes AKT degradation and thus should in turn attenuate secretion of IGF-BP2. HER-2 ECD is a shed form of HER-2 that circulates in ...
The CCN2 protein is thought to consist of four separate modules. Module 1 is identical to insulin-like growth factor binding protein, module 2 consists of a chordin-like cysteine-rich domain, module 3 is composed of a thrombospondin type 1 domain and module 4 is designated as the CT module or cysteine knot. Modules 1 and 2 make up the N-terminal domain and are linked by a hinge region to the C-terminal domain which is made up of modules 3 and 4 [31, 32]. The ELISA analysis used in our study detects C-terminal CCN2 which translates into detection of both C-terminal fragments and whole CCN2. Our analysis is not able to detect N-terminal CCN2 fragments. Other studies have evaluated the utility of N-terminal CCN2 as a marker of intraocular fibrosis and in scleroderma. In these studies, neither C-terminal nor whole CCN2 were elevated in disease. As as result, it has been postulated that during a fibrotic response, in vivo CCN2 is cleaved resulting in N-terminal fragments which are excreted into the ...
Insulin-like growth factor-binding protein 3, also known as IGFBP-3, is a protein that in humans is encoded by the IGFBP3 gene. IGFBP-3 is one of six IGF binding proteins (IGFBP-1 to IGFBP-6) that have highly conserved structures and bind the insulin-like growth factors IGF-1 and IGF-2 with high affinity. IGFBP-7, sometimes inappropriately included in this family, shares neither the conserved structural features nor the high IGF affinity. IGFBP-3 was first isolated, characterized, and quantitated in human plasma, in 1986. It has well-documented functions in the circulation, in the extracellular environment, and inside cells. It is the main IGF transport protein in the bloodstream, where it carries the growth factors predominantly in stable complexes that contain the binding protein, either IGF-1 or IGF-2, and a third protein called the acid-labile subunit or ALS. For IGFs to reach the tissues from the bloodstream, the circulating complexes are believed to partly dissociate, possibly enhanced by ...
J:58580 van Kleffens M, Groffen CA, Dits NF, Lindenbergh-Kortleve DJ, Schuller AG, Bradshaw SL, Pintar JE, Zwarthoff EC, Drop SL, van Neck JW, Generation of antisera to mouse insulin-like growth factor binding proteins (IGFBP)-1 to -6: comparison of IGFBP protein and messenger ribonucleic acid localization in the mouse embryo. Endocrinology. 1999 Dec;140(12):5944-52 ...